1. ONCY announces a corporate call on May 14, 2025. 2. The call will discuss Q1 2025 financial results and corporate updates. 3. Pelareorep shows promise in breast and pancreatic cancer studies. 4. Combination clinical trials with pelareorep are advancing towards registrational studies. 5. Fast Track designation from FDA boosts pelareorep's development strategy.
ONCY's consistent advancements in clinical trials and FDA designations typically lead to positive sentiment.
The corporate update and trial progress are critical for investor confidence and stock valuation.
Positive developments in clinical trials can lead to sustained interest and value in the long run.
to take place on Wednesday, May 14, 2025, at 4:30 p.m. ET
SAN DIEGO and CALGARY, AB, May 6, 2025 Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Wednesday, May 14, 2025, at 4:30 p.m. ET to discuss a corporate update and financial results for the first quarter of 2025.
Date: Wednesday, May 14, 2025
Time: 4:30 p.m. ET
Dial In – North American Toll-Free: (888) 510-2154
Dial In – International: (437) 900-0527
RapidConnect: to join the conference call without operator assistance, please click here
Conference ID (if needed): 28038
Webcast: please click here
A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here, and will be archived for three months. A dial-in replay will be available for one week and can be accessed by dialing (888) 660-6345 (North America) or (289) 819-1450 (International) and using replay code: 28038#.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
Jon Patton
Director of IR & Communication
[email protected]
Mike Moyer
LifeSci Advisors
+1-617-308-4306
[email protected]
Michael Rubenstein
LifeSci Communications
[email protected]
SOURCE Oncolytics Biotech® Inc.